Nutritional and Anti-infective Interventions for Malnutrition in Pregnancy (Beleuman Welbodi)

Sponsor
Washington University School of Medicine (Other)
Overall Status
Completed
CT.gov ID
NCT03079388
Collaborator
The Children's Investment Fund Foundation (Other)
1,489
1
2
35.9
41.5

Study Details

Study Description

Brief Summary

Acute malnutrition in pregnancy is a risk factor for adverse outcomes in mothers and their unborn children. Undernutrition during pregnancy can result in maternal complications such as life-threatening hemorrhage and hypertensive disorders of pregnancy and infant complications such as intrauterine growth retardation, low birth weight, pre-term delivery and poor cognitive development. Poor women in the developing world are at heightened risk of malnutrition due to inadequate dietary intake and are subject to transmission of a number of infections including malaria, intestinal helminths, and genitourinary infections. Food interventions for malnutrition may be less effective under conditions with excessive inflammation and infection, and especially so during pregnancy. Without specifically addressing treatment for infections, undernourished mothers may be less responsive to nutritional interventions. The benefits of treating both malnutrition and common infections simultaneously remain largely unstudied. This study tests the hypothesis that malnourished pregnant women receiving 100 grams per day of a specially formulated ready-to-use supplementary food in addition to a combination of 5 anti-infective interventions will have greater weight gain in pregnancy and deliver larger, longer infants than women receiving the standard of care. The outcome of the pregnancy and maternal nutritional status will be followed until 6 months after delivery.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Ready-to-use-supplementary food
  • Dietary Supplement: Corn-soy-blend
  • Drug: Monthly intermittent preventive treatment of malaria during pregnancy (IPTp)
  • Drug: Standard intermittent preventive treatment of malaria during pregnancy (IPTp)
  • Other: Insecticide-treated mosquito net
  • Drug: Azithromycin
  • Drug: Albendazole
  • Combination Product: Bacterial vaginosis testing and treatment
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
1489 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Randomized Control Trial of the Use of Supplementary Food and Measures to Control Inflammation in Malnourished Pregnant Women to Improve Birth Outcomes
Actual Study Start Date :
Feb 27, 2017
Actual Primary Completion Date :
Sep 24, 2019
Actual Study Completion Date :
Feb 24, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Ready-to-use supplementary food + anti-infective bundle

The women randomized to this arm will receive a ready-to-use-supplementary food (RUSF) designed specifically for pregnancy. The RUSF will provide a total of 520 kcal, 18 g protein, and 200% of recommended daily allowance (RDA) for most micronutrients during pregnancy. The supplement is also optimized to provide excellent protein quality and optimal polyunsaturated fatty acid composition. These women will receive 5 anti-infective interventions: 1) insecticide-treated mosquito net, 2) monthly intermittent preventive treatment of malaria during pregnancy (IPTp) 3) azithromycin at the second and third trimester 4) albendazole given in second trimester, and 5) bacterial vaginosis testing and treatment at enrollment and again at weeks 28-34

Dietary Supplement: Ready-to-use-supplementary food
Specially formulated supplementary food for pregnancy

Drug: Monthly intermittent preventive treatment of malaria during pregnancy (IPTp)
Sulfadoxine-pyrimethamine (500 mg / 25 mg) given every 4 weeks, beginning at enrollment or at 13 weeks' gestation, whichever is later.
Other Names:
  • Sulfadoxine-pyrimethamine
  • Other: Insecticide-treated mosquito net
    An insecticide-treated mosquito net at the time of enrollment into the study.

    Drug: Azithromycin
    Azithromycin 1 gram given once in second trimester and again during weeks 28-34 of gestation.

    Drug: Albendazole
    Single dose albendazole 400mg given in the second trimester.

    Combination Product: Bacterial vaginosis testing and treatment
    Testing for bacterial vaginosis at enrollment and again at weeks 28-34 using a rapid diagnostic test for sialidase. Those with positive tests will receive extended release metronidazole 750mg daily for 7 days.

    Active Comparator: Corn-soy-blend

    The women randomized to this arm will receive the standard of care for Sierra Leone. The treatment provided to women in this group includes 3.5 kg super cereal with 350 g vegetable oil every two weeks. This provides 250 mg portion/day of the super cereal and 25g oil/day for the mother. Women will receive the food for the duration of their pregnancy. These women will receive the current recommendations of the government of Sierra Leone, which includes standard intermittent preventive treatment of malaria during pregnancy (IPTp) of 2 doses of sulfadoxine/ pyrimethamine, iron and folic acid supplement with a goal of 90 pills/pregnancy, an insecticide-treated mosquito net, and albendazole for deworming in the second trimester.

    Dietary Supplement: Corn-soy-blend
    Standard of care for malnutrition in pregnancy in Sierra Leone

    Drug: Standard intermittent preventive treatment of malaria during pregnancy (IPTp)
    Standard of care for Sierra Leone is 2 doses of sulfadoxine/ pyrimethamine (500mg/ 25mg).
    Other Names:
  • Sulfadoxine-pyrimethamine
  • Other: Insecticide-treated mosquito net
    An insecticide-treated mosquito net at the time of enrollment into the study.

    Drug: Albendazole
    Single dose albendazole 400mg given in the second trimester.

    Outcome Measures

    Primary Outcome Measures

    1. Infant birth length [up to 40 weeks]

      mean birth length of infants born to mothers in the study

    Secondary Outcome Measures

    1. Maternal weight gain [up to 40 weeks]

      Average weekly weight gain of women in the study

    2. Proportion recovered from maternal malnutrition [up to 40 weeks]

      proportion of women who reach mid-upper-arm circumference (MUAC) > 23 cm

    3. Premature delivery [up to 36 weeks]

      proportion of infants born prematurely

    4. Newborn head circumference [up to 40 weeks]

      mean head circumference of infants born to women in the study

    5. Infant birth weight [up to 40 weeks]

      mean birth weights of infants born to mothers in the study

    6. Infant weight at 6 weeks, 3 and 6 months [up to 6 months]

      infant ponderal growth

    7. Infant length at 6 weeks, 3 and 6 months [up to 6 months]

      infant linear growth

    8. Infant survival at 3 and 6 months [up to 6 months]

      survival of infants in the study

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    14 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Pregnant women and consenting to study participation

    • Fundal height not greater than 32 cm

    • Mid-upper arm circumference ≤23 cm

    • Planning to reside in the study area during pregnancy and 6 months post partum

    • Attending 1 of the 40 antenatal clinic sites

    Exclusion Criteria:
    • < 16 years of age without adult willing to consent

    • Known pregnancy complications such as gestational diabetes, pre-eclampsia, hypertension

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 1 Moriba Street Pujehun Pujehun District Sierra Leone

    Sponsors and Collaborators

    • Washington University School of Medicine
    • The Children's Investment Fund Foundation

    Investigators

    • Study Chair: Mark J Manary, MD, Washington University School of Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Washington University School of Medicine
    ClinicalTrials.gov Identifier:
    NCT03079388
    Other Study ID Numbers:
    • 201611119
    First Posted:
    Mar 14, 2017
    Last Update Posted:
    Jan 7, 2021
    Last Verified:
    Jan 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 7, 2021